Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Letestu · SciRah

Researcher profile · Semantic Scholar

R. Letestu

Share profile

R. Letestu — researcher profile on SciRah

h-index: 27
Works: 115
Citations: 2,474

Most-cited papers

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
A. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor +47 more
2015Leukemia241 citations Open access
Semantic Scholar
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
A. Rawstron, S. Böttcher, R. Letestu, N. Villamor +14 more
2013Leukemia199 citations
Semantic Scholar
Rituximab for patients with refractory mucous membrane pemphigoid.
C. Le Roux-Villet, C. Prost-Squarcioni, M. Alexandre, F. Caux +9 more
2011Archives of Dermatology134 citations Open access
Semantic Scholar
Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study.
A. Quinquenel, L. Fornecker, R. Letestu, L. Ysebaert +14 more
2019Blood106 citations Open access
Semantic Scholar
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
F. Garnache-Ottou, C. Vidal, S. Biichlé, F. Renosi +122 more
2019Blood Advances103 citations Open access
Semantic Scholar
Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.
Pierre‐Antoine Deglesne, N. Chevallier, R. Letestu, F. Baran-Marszak +7 more
2006Cancer Research103 citations
Semantic Scholar
Evaluation of ZAP‐70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process
R. Letestu, A. Rawstron, P. Ghia, N. Villamor +19 more
2006Cytometry. Part B, Clinical cytometry99 citations Open access
Semantic Scholar
Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.
Amalia Vlad, Pierre‐Antoine Deglesne, R. Letestu, S. Saint-Georges +5 more
2009Cancer Research95 citations Open access
Semantic Scholar
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
S. Leprêtre, T. Aurran, B. Mahé, B. Cazin +15 more
2012Blood93 citations
Semantic Scholar
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
C. Herling, F. Cymbalista, Carolin Groß-Ophoff-Müller, J. Bahlo +23 more
2020Leukemia70 citations Open access
Semantic Scholar
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
C. Le Roy, Pierre‐Antoine Deglesne, N. Chevallier, Taoufik Beitar +7 more
2012Blood63 citations
Semantic Scholar
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
C. Bagacean, R. Letestu, C. Al-nawakil, S. Brichler +22 more
2021Blood Advances48 citations Open access
Semantic Scholar
Flow cytometry APC‐tandem dyes are degraded through a cell‐dependent mechanism
C. Le Roy, N. Varin-Blank, F. Ajchenbaum‐Cymbalista, R. Letestu
2009Cytometry Part A46 citations
Semantic Scholar
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.
R. Letestu, V. Lévy, V. Eclache, F. Baran-Marszak +9 more
2010Blood45 citations Open access
Semantic Scholar
Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT‐X) determined by the Sysmex XE‐2100TM
G. Le Roux, Amalia Vlad, Virginie Eclache, C. Malanquin +9 more
2010International Journal of Laboratory Hematology42 citations
Semantic Scholar
Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis
F. Lefrère, S. Zohar, Sandrine Beaudier, F. Audat +8 more
2007Transfusion38 citations
Semantic Scholar
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
A. Quinquenel, T. Aurran-Schleinitz, A. Clavert, F. Cymbalista +20 more
2020HemaSphere35 citations Open access
Semantic Scholar
Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring
R. Letestu, C. Marzac, F. Audat, R. Belhocine +8 more
2007Leukemia and Lymphoma35 citations
Semantic Scholar
National standardization of ZAP‐70 determination by flow cytometry: The French experience
M. Le Garff-Tavernier, M. Ticchioni, M. Brissard, C. Salmon +6 more
2007Cytometry. Part B, Clinical cytometry30 citations Open access
Semantic Scholar
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
C. Dartigeas, E. Van Den Neste, J. Léger, H. Maisonneuve +21 more
2017The Lancet Haematology29 citations
Semantic Scholar
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes
Grégory Lazarian, E. Tausch, V. Eclache, Amel Sebaa +10 more
2016International Journal of Cancer29 citations Open access
Semantic Scholar
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
R. Letestu, Abdelmalek Dahmani, M. Boubaya, L. Baseggio +25 more
2020Leukemia24 citations Open access
Semantic Scholar
Deciphering leukemic B-cell chronic lymphoproliferative disorders
V. Ugo, N. Leporrier, V. Salaun, R. Letestu +11 more
2006Leukemia and Lymphoma24 citations
Semantic Scholar
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study
Anne-Laure Gagez, I. Duroux-Richard, S. Leprêtre, F. Orsini-Piocelle +12 more
2017Haematologica23 citations Open access
Semantic Scholar
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia
C. Dartigeas, E. Van Den Neste, C. Berthou, H. Maisonneuve +21 more
2016Leukemia and Lymphoma22 citations
Semantic Scholar
Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
A. Quinquenel, C. al Nawakil, F. Baran-Marszak, V. Eclache +8 more
2015American journal of hematology/oncology21 citations
Semantic Scholar
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +30 more
2019The Lancet Haematology20 citations Open access
Semantic Scholar
Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy
M. Capovilla, J. Cayuela, C. Bilhou-Nabera, C. Gardin +4 more
2007European Journal of Haematology19 citations
Semantic Scholar
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study
I. Duroux-Richard, Anne-Laure Gagez, E. Alaterre, R. Letestu +7 more
2022Frontiers in Immunology13 citations Open access
Semantic Scholar
Induction of endoplasmic reticulum calcium pump expression during early leukemic B cell differentiation
Lamia Aït Ghezali, Atousa Arbabian, H. Roudot, J. Brouland +8 more
2017Journal of experimental & clinical cancer research : CR13 citations Open access
Semantic Scholar
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
A. Michallet, R. Letestu, M. Le Garff-Tavernier, C. Aanei +30 more
2020Blood12 citations Open access
Semantic Scholar
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, L. Campos +29 more
2023Blood Advances11 citations Open access
Semantic Scholar
Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non‐Hodgkin lymphoma
A. Debliquis, L. Baseggio, S. Bouyer, J. Guy +15 more
2020Cytometry. Part B, Clinical cytometry11 citations Open access
Semantic Scholar
Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
Adriana Plesa, Stéphanie Mathis, F. Dumézy, A. Lhoumeau +34 more
2024Blood10 citations
Semantic Scholar
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
G. Cartron, R. Letestu, C. Dartigeas, M. Tout +18 more
2018Haematologica10 citations Open access
Semantic Scholar
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression
A. Mékinian, A. Quinquenel, Koceïla Ait Belkacem, F. Kanoun +10 more
2023Cancer Gene Therapy9 citations Open access
Semantic Scholar
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
E. Van Den Neste, R. Letestu, T. Aurran-Schleinitz, L. Ysebaert +3 more
2012Leukemia and Lymphoma8 citations
Semantic Scholar
TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma
Grégory Lazarian, Lotfi Chemali, Merieme Bensalah, Carla Zindel +14 more
2025American journal of hematology/oncology7 citations Open access
Semantic Scholar
Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (≥ 65 years) CLL patients: Results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606).
C. Dartigeas, E. Van Den Neste, H. Maisonneuve, C. Berthou +16 more
20167 citations
Semantic Scholar
Evaluation of Fluorescently Labeled Aerolysin as a New Kind of Reagent for Flow Cytometry Tests: Optimization of Use of FLAER, Hints, and Limits.
Abdelmalek Dahmani, H. Roudot, F. Cymbalista, R. Letestu
2016American Journal of Clinical Pathology7 citations Open access
Semantic Scholar
Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries.
A. Debliquis, O. Wagner-Ballon, M. Le Garff-Tavernier, C. Fossat +3 more
2015American Journal of Clinical Pathology7 citations
Semantic Scholar
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
C. Kelaidi, T. Braun, R. Arana, Alice Marceau-Renaut +12 more
2018Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis6 citations
Semantic Scholar
High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group
A. Quinquenel, L. Fornecker, R. Letestu, Carole Fleury +13 more
2018Blood6 citations
Semantic Scholar
Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospecific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods
R. Letestu, G. Cartron, S. Leprêtre, M. Le Garff-Tavernier +9 more
20146 citations
Semantic Scholar
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
A. Michallet, R. Letestu, M. Legarff, S. Morisset +30 more
2024Blood5 citations
Semantic Scholar
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia
P. Feugier, T. Aurran, B. Mahé, R. Letestu +17 more
2018Haematologica5 citations Open access
Semantic Scholar
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, Stéphane Morisset +38 more
2025EClinicalMedicine4 citations Open access
Semantic Scholar
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
Grégory Lazarian, F. Theves, M. Hormi, R. Letestu +22 more
2022American journal of hematology/oncology4 citations Open access
Semantic Scholar
AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
A. Plesa, F. Dumézy, Stéphanie Mathis, A. Lhoumeau +32 more
2022Blood4 citations Open access
Semantic Scholar
Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +29 more
20174 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Cymbalista×22
Invite
F. Cymbalista — researcher profile on SciRah
S. Leprêtre×19
Invite
S. Leprêtre — researcher profile on SciRah
A. Delmer×16
Invite
A. Delmer — researcher profile on SciRah
V. Lévy×16
Invite
V. Lévy — researcher profile on SciRah

×14

Invite

P. Feugier — researcher profile on SciRah

Invite

V. Leblond — researcher profile on SciRah

O. Tournilhac×13

Invite

O. Tournilhac — researcher profile on SciRah

C. Dartigeas×13

Invite

C. Dartigeas — researcher profile on SciRah

M. Dilhuydy×12

Invite

M. Dilhuydy — researcher profile on SciRah

A. Michallet×12

Invite

A. Michallet — researcher profile on SciRah

M. Le Garff-Tavernier×12

Invite

M. Le Garff-Tavernier — researcher profile on SciRah

F. Ajchenbaum‐Cymbalista×12

Invite

F. Ajchenbaum‐Cymbalista — researcher profile on SciRah